Agios Pharmaceuticals vs Akebia Therapeutics
AGIO and AKBA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGIO and AKBA compare
Agios Pharmaceuticals is the larger company, worth 16 times as much as Akebia Therapeutics ($1.8B against $111M).
Agios Pharmaceuticals grew revenue faster over the last twelve months (141% versus 7.5% for Akebia Therapeutics).
Akebia Therapeutics keeps more of each dollar of sales as profit, with a net margin of −13.5% compared with −418% at Agios Pharmaceuticals.
Agios Pharmaceuticals scores higher on the StockData Score (12 against 6 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGIO | AKBA |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $111M |
| Share price | $29.89 | $0.400 |
| Change, 1 year | −31.5% | −76.0% |
| Change, 5 years | −18.0% | −85.0% |
| Beta (5Y) | 1.54 | 1.20 |
| Employees | 539 | 194 |
| StockData Score | ||
| Total score | 12 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 18.1× | 0.5× (better) |
| P/B | 1.7× (better) | 4.4× |
| P/FCF | – | 2.8× |
| FCF yield | −20.5% | 36.3% (better) |
| Fair value | $27.70 | – |
| Margin of safety | −7.9% | – |
| Growth | ||
| Revenue growth (TTM) | 141% (better) | 7.5% |
| Revenue growth, 5Y average | – | −4.3% |
| Net income growth (TTM) | −163% | – |
| EPS growth (TTM) | −163% | – |
| Profitability | ||
| Gross margin | 92.0% (better) | 79.6% |
| Operating margin | −467% | −6.9% (better) |
| Net margin | −418% | −13.5% (better) |
| FCF margin | −371% | 18.4% (better) |
| Return on equity | −34.3% (better) | −109% |
| Return on invested capital | −759% | – |
| Financial health | ||
| Debt / equity | 0.00 | 1.98 (better) |
| Current ratio | 10.22 (better) | 1.43 |
| Altman Z-score | 11.45 (better) | −5.89 |
| Piotroski F-score | 1 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 111% | 39.7% |
| Held by insiders | 1.1% | 2.9% |
| Insider net buying, 12 months | −$4.9M | −$876K (better) |
| Short interest, % of float | 11.1% | 10.1% |
Go deeper
- AGIO stock overview
- AGIO income statement
- AGIO valuation and score
- AKBA stock overview
- AKBA income statement
- AKBA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.